Stock Ratings / Health Care / DCGO / insiders

PIII (38) BMGL (58) CCM (22) EUDA (39) ⌘ Pro Terminal →

DocGo Inc. (DCGO) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Q: Are DCGO insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies DCGO leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

$0.27 -2.43% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

DocGo Inc. (DCGO) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $27.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-7.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DCGO)Realized 20D OHLCV Swing Band: ±12.5%

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

DCGO Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (DCGO)

No recent open-market Form 4 cluster sales or emergency dumps flagged on DCGO. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DCGO)

✓Walkthrough of DCGO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

DCGO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -61.97%📐 HORIZONTAL RANGE

2026-10-30O $0.27H $0.27L $0.24C $0.27VOL 1.72M

RES: $0.73SUP: $0.21SMA50: $0.35SMA200: $0.57

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DCGO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DCGO Butterfly Map → + Track DCGO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -47.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on DCGO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DCGO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for DCGO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DCGO)

Health Care Rank #558 of 1016 ⚔️ PIII vs DCGO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DCGO vs. PIII, BMGL, CCM, EUDA)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, DocGo Inc. (DCGO) ranks #558 by composite RQD confidence (43/100, grade D-) and #815 by equity capitalization ($27.0M). Within this direct 5-issuer industry benchmark cohort, DCGO leads on earnings valuation at N/A trailing P/E, while DCGO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. BMGL currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with DCGO at 43/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
DCGO ACTIVE DocGo Inc.	D-	43/100	—	—	-35.0%	-2.43%	$27.0M	Benchmark Subject
PIII P3 Health Partners Inc. (Class A)	D-	38/100	—	—	-35.0%	+4.22%	$30.5M	/piii-vs-dcgo →
BMGL Basel Medical Group Ltd	D+	58/100	—	—	—	+3.26%	$36.0M	/bmgl-vs-dcgo →
CCM Concord Medical Services Holdings Limited (Each represents thirty (30) ) (Class A)	E	22/100	—	5.7%	-35.0%	-4.93%	$15.9M	/ccm-vs-dcgo →
EUDA EUDA Health Holdings Limited	D-	39/100	—	43.9%	-35.0%	+1.31%	$46.4M	/euda-vs-dcgo →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001822359

In its most recent audited fiscal period (FY2025, filed 2025-12-31), DocGo Inc. (DCGO) reported GAAP revenue of $322.2M (-47.7% vs. FY2024 revenue of $616.6M , and -48.4% cumulative change since FY2023) , GAAP net income of -$196.4M, operating cash flow of $34.5M, and free cash flow of $29.9M (-55.0% YoY). On the balance sheet, DCGO closed FY2025 with $217.1M in total assets against $183.8K in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$322.2M	-$196.4M	$34.5M	$29.9M	$217.1M	$183.8K
FY2024 (FY)	2024-12-31	$616.6M	$13.4M	$70.1M	$66.5M	$455.6M	$5.2K
FY2023 (FY)	2023-12-31	$624.3M	$10.0M	-$64.5M	-$64.5M	—	—

3. DCGO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DCGO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, DocGo Inc. (NASDAQ: DCGO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $0.27 (-2.43% 1D, market cap $27.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, DCGO ranks #558 in composite RQD confidence.

How does DCGO compare to PIII and BMGL in the Health Care sector?

Within the Health Care sector (Medical/Nursing Services), DCGO carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PIII (P3 Health Partners Inc. (Class A)) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $30.5M) and BMGL (Basel Medical Group Ltd) posts a D+ grade (58/100 RQD, P/E N/A, ROIC —, cap $36.0M). Among the 5-stock peer group, DCGO leads on earnings multiple (N/A) while DCGO leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for DCGO?

Per DCGO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001822359), DocGo Inc. generated $322.2M in revenue (-47.7% YoY), -$196.4M in net income, and $29.9M in free cash flow against $217.1M in total assets and $183.8K in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is DCGO trading relative to its 50-day, 200-day, and 52-week technical levels?

DCGO last traded at $0.27 (-2.43% on volume of 681,449 shares), positioning the stock -22.86% below its 50-day simple moving average ($0.35) and -52.63% below its 200-day simple moving average ($0.57). Across its 52-week range of $0.24 to $1.17, DCGO sits at the 3.2% percentile with a 14-day RSI of 31.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.30).

DCGO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are DCGO insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies DCGO leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: DCGO RQD Cockpit DCGO 12M Forecast DCGO Earnings & Move DCGO Dividends & DRIP DCGO Insiders & 13F DCGO Whale Options DCGO Profit Sankey DCGO News & Why